ELEric Lartigau

Eric Lartigau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Lartigau has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy

    by Eymeric Le Reun, Adeline Granzotto, Adeline Pêtre, Larry Bodgi, Guillaume Beldjoudi, Thomas Lacornerie, Véronique Vallet, Audrey Bouchet, Joëlle Al-Choboq, Michel Bourguignon, et al.

    Stereotactic body radiation therapy (SBRT) has made the hypofractionation of high doses delivered in a few sessions more acceptable. While the benefits of hypofractionated SBRT have been attributed to additional vascular, immune effects, or specific cell deaths, a radiobiological and mechanistic model is still needed. By considering each session of SBRT, the dose is divided into hundreds of minibeams delivering some fractions of Gy. In such a dose range, the hypersensitivity to low dose (HRS) phenomenon can occur. HRS produces a biological effect equivalent to that produced by a dose 5-to-10 times higher. To examine whether HRS could contribute to enhancing radiation effects under SBRT conditions, we exposed tumor cells of different HRS statuses to SBRT. Four human HRS-positive and two HRS-negative tumor cell lines were exposed to different dose delivery modes: a single dose of 0.2 Gy, 2 Gy, 10 × 0.2 Gy, and a single dose of 2 Gy using a non-coplanar isocentric minibeams irradiation mode were delivered. Anti-γH2AX immunofluorescence, assessing DNA double-strand breaks (DSB), was applied. In the HRS-positive cells, the DSB produced by 10 × 0.2 Gy and 2 Gy, delivered by tens of minibeams, appeared to be more severe, and they provided more highly damaged cells than in the HRS-negative cells, suggesting that more severe DSB are induced in the “SBRT modes” conditions when HRS occurs in tumor. Each SBRT session can be viewed as hyperfractionated dose delivery by means of hundreds of low dose minibeams. Under current SBRT conditions (i.e., low dose per minibeam and not using ultra-high dose-rate), the response of HRS-positive tumors to SBRT may be enhanced significantly. Interestingly, similar conclusions were reached with HRS-positive and HRS-negative untransformed fibroblast cell lines, suggesting that the HRS phenomenon may also impact the risk of post-RT tissue overreactions.


  • Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial

    by Alicia Le Bras, Yazid Belkacemi, Celine Bourgier, Isabelle Gabelle-Flandin, Adeline Petit, Philippe Guilbert, Julien Geffrelot, Severine Racadot, Eleonor Rivin Del Campo, Chantal Hanzen, et al.


  • Open Access

    Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety

    by Isaure Roquette, Emilie Bogart, Thomas Lacornerie, Massih Ningarhari, Jean-Emmanuel Bibault, Marie-Cecile Le Deley, Eric F. Lartigau, David Pasquier, Xavier Mirabel

    This study aimed to describe patient characteristics, treatment efficacy, and safety in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiation therapy (SBRT). We retrospectively analyzed data of 318 patients with 375 HCC treated between June 2007 and December 2018. Efficacy (overall survival [OS], relapse-free survival, and local control) and acute and late toxicities were described. The median follow-up period was 70.2 months. Most patients were treated with 45 Gy in three fractions. The median (range) PTV volume was 90.7 (2.6–1067.6) cc. The local control rate at 24 and 60 months was 94% (91–97%) and 94% (91–97%), respectively. Relapse-free survival at 12, 24, and 60 months was 62% (55–67%), 29% (23–36%), and 13% (8–19%), respectively. OS at 12, 24, and 60 months was 72% (95%CI 67–77%), 44% (38–50%), and 11% (7–15%), respectively. Approximately 51% and 38% experienced acute and late toxicity, respectively. Child-Pugh score B-C, high BCLC score, portal thrombosis, high GTV volume, and higher PTV volume reported on total hepatic volume ratio were significantly associated with OS. SBRT is efficient for the management of HCC with a favorable toxicity profile. The outcome is highly related to the natural evolution of the underlying cirrhosis.


  • Open Access

    Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer

    by Benoît Bataille, Bennadji Raoudha, Florence Le Tinier, Laurent Basson, Alexandre Escande, Hélène Langin, Emmanuelle Tresch, Frederik Crop, Franck Darloy, Damien Carlier, et al.

    The objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 Gy in 25 fractions to the breast or chest wall and to lymph node areas, with a simultaneous integrated boost at a dose of 60 Gy at the tumor bed in cases of breast conservative surgery. We included 288 patients, 168 and 120 treated with breast-conserving surgery and mastectomy respectively. Two hundred sixty patients (90.3%) received lymph node irradiation. Median follow-up was 25 months (6–48). Acute dermatitis was observed in 278 patients (96.5%), mostly grade 1 (59.7%). The aesthetic aspect of the breast at one year was reported as “good” or “excellent” in 84.6% of patients. The patients’ quality of life improved over time, especially those treated with chemotherapy. The two-year overall survival and disease-free survival were 97.8% (95% confidence interval (CI): 94.1–99.2%), and 93.4% (95% CI: 89.2–96.0%) respectively. Tomotherapy for locally advanced BC has acceptable toxicity, supporting its use in this indication; however, longer follow-up is needed to assess long-term outcomes.


  • Open Access

    Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91

    by Evelyn E.C. de Jong, Matthias Guckenberger, Nicolaus Andratschke, Karin Dieckmann, Mischa S. Hoogeman, Maaike Milder, Ditte Sloth Møller, Tine Bisballe Nyeng, Stephanie Tanadini-Lang, Eric Lartigau, et al.


  • Open Access

    BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol

    by David Pasquier, Emilie Bogart, François Bonodeau, Thomas Lacornerie, Eric Lartigau, Igor Latorzeff

    Prospective trials have demonstrated the advantage of dose-escalated radiotherapy for the biochemical and clinical control of intermediate risk prostate cancer. Dose escalation improves outcomes but increases risks of urinary and bowel toxicity. Recently the contribution of “spacers” positioned in the septum between the rectum and the prostate could improve the functional results of intensity modulated radiation therapy (IMRT). To date most of the evaluated devices were polyethylen glycol (PEG) and hyaluronic acid (HA). Men on the Spacer arm had decreased bowel toxicity and less decline in both urinary and bowel quality of life as compared to Control men in a randomized trial. This is an interventional, multi-center study to evaluate the use of biodegradable inflatable balloon for patients with intermediate risk prostate cancer treated by IMRT (74 to 80 Gy, 2 Gy/fraction) with daily image guided radiotherapy. This multicenter prospective study will yield new data regarding dosimetric gain and implantation stages of Bioprotect balloon. Acute and late toxicities and quality of life will be registered too. NCT02478112 , date of registration: 15/06/2015.


  • Open Access

    Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center

    by Thomas Leroy, Thomas Lacornerie, Emilie Bogart, Philippe Nickers, Eric Lartigau, David Pasquier

    Currently, there is no standard option for local salvage treatment for local prostate cancer recurrence after radiotherapy. Our objective was to investigate the feasibility and efficiency of Robotic Stereotactic Body Radiation Therapy (SBRT) in this clinical setting. We retrospectively reviewed patients who were treated at our institution with SBRT for local prostate cancer recurrence after External Beam Radiation Therapy (EBRT) or brachytherapy. Multidisciplinary staff approved the treatment, and recurrence was biopsy-proven when feasible. A dose of 36 Gy was prescribed in six fractions. Treatment was delivered every other day. Between August 2011 and February 2014, 23 patients were treated with SBRT for intra-prostate cancer recurrence with a median follow up of 22 months (6 to 40). Twenty patients had biopsy-proven recurrence. For 19 patients, EBRT was the initial treatment and in four patients, brachytherapy was the initial treatment; the median relapse-time from initial treatment was 65 months (28 to 150). At relapse, 10 patients had an extra-capsular extension. Fourteen patients were treated with androgen deprivation that could be stopped after a median of 1 month after SBRT (range 0–24). A PSA decrease occurred in 82.6% of the patients after SBRT. The 2-year disease-free survival and overall survival rates were 54 and 100%, respectively. Disease progression was observed for nine patients (39.1%) (five local, three metastatic and one nodal progression) after a median of 20 months (7–40 months). The median nadir PSA was 0.35 ng/ml and was achieved after a median of 8 months (1 to 30) after treatment. We observed no grade 4 or 5 toxicity. Two patients presented with grade 3 toxicities (two Cystitis and one neuralgia). Other toxicities included urinary toxicities (five grade 2 and nine grade 1) and rectal toxicities (two grade 2 and two grade 1). SBRT for local prostate cancer recurrence seems feasible and well tolerated with a short follow up. Prospective evaluation is needed.


  • Open Access

    EP-1694: DW-MRI as a predictor of tumor response to hypofractionated stereotactic boost for prostate cancer

    by D. Pasquier, A. Hadj Henni, E. Tresch, N. Reynaert, E. Lartigau, O. Colot, N. Betrouni

  • Open Access

    EP-1093: Hypofractioned robotic stereotactic radiotherapy of Head and neck Paragangliomas

    by F. Meniai-Merzouki, B. Coche-Dequeant, E. Bogart, T. Lacornerie, X. Mirabel, E. Lartigau, D. Pasquier

  • Risque de récidive locale en fonction de la classification moléculaire, exemple du cancer du sein

    by B. Bataille, L. Boulanger, N. Kotecki, A. Jouin, E. Lartigau, D. Pasquier

    Résumé Le contrôle local est un enjeu majeur du traitement du cancer. Quelle que soit la tumeur primitive, la récidive locale expose à un risque de détérioration de la qualité de vie et d’extension métastatique. Le cancer du sein illustre parfaitement cette problématique. De nombreux progrès en recherche fondamentale et translationnelle ont permis la naissance d’une nouvelle classification en cancérologie mammaire fondée sur des données moléculaires. L’impact du sous-type moléculaire sur la dissémination à distance est bien connu, mais son influence sur le contrôle local est moins bien déterminée. Il semble que les carcinomes mammaires les plus à risque de récidive locale soient les tumeurs basal-like et HER-2, comme cela a été démontré pour la dissémination métastatique. Une meilleure connaissance de facteurs influençant la récidive locale pourrait amener à une médecine adaptée à la biologie tumorale, avec une désescalade thérapeutique pour les formes de meilleur pronostic, ainsi qu’une intensification de la prise en charge pour des formes défavorables.